Report workspace tools

NCT00179010TERMINATEDanonymous

Use of AMP to Improve Tissue Delivery of Adenosine

Sponsor

Source record

Vanderbilt University Medical Center

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

Adenosine, Adenosine Mono Phosphate (AMP)

Indication / condition

AI-normalized

Ischemia

Intervention

Source record

Adenosine, Adenosine Mono Phosphate (AMP)

Source & freshness

Source record

NCT ID

NCT00179010

Original source

ClinicalTrials.gov

Source last updated

May 07, 2019

Ingested at

Jun 08, 2026

Internal sync

Jun 08, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00179010

Title

Use of AMP to Improve Tissue Delivery of Adenosine

Sponsor

Vanderbilt University Medical Center

Status

TERMINATED

Phase

PHASE1

Condition raw

Ischemia

Condition normalized

Ischemia

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Adenosine, Adenosine Mono Phosphate (AMP)

Target normalized

Adenosine, Adenosine Mono Phosphate (AMP)

Interventions

Adenosine, Adenosine Mono Phosphate (AMP)

Public preview

Source record

Adenosine and AMP are substances normally present in the body. Adenosine is also given for the treatment of some heart rhythm problems and may be used to reduce heart damage during heart attacks. The problem in using adenosine is that it is taken up by cells and, therefore, very little of the adenosine we give by vein or in the artery actually reaches the tissue. We propose to use AMP as a way to improve delivery of adenosine. AMP is inactive by itself, but is converted to adenosine in tissue. We hope that by giving AMP we will increase levels of adenosine in tissue. To see if this is true, we will give either adenosine or AMP into the forearm artery while we measure how much adenosine reaches the forearm tissue.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account

Create a free account first, then unlock a single report, buy credits or subscribe.